Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 8,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Gastroparesis
Interventions: EndoFLIP; Device
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Noise Exposure, Sedative Withdrawal Delirium, Sedative Toxicity
Interventions: Decibel Monitor; Other
Lead sponsor: Children's National Research Institute; Other
Eligibility: Up to 22 Years
Enrollment: 64 participants
Timeline: 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 477 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Suspected or Documented Gram-negative Bacterial Infection
Interventions: IMI/REL, Active Control, Oral Switch; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: Up to 17 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • Long Beach, California • San Diego, California + 5 more

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions: 2'-Fucosyllactose, Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 11 Years to 25 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 3
States / cities: Hartford, Connecticut • Cincinnati, Ohio • Columbus, Ohio

Conditions: Moderate-to-Severe Atopic Dermatitis
Interventions: Nemolizumab; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 14
States / cities: Fountain Valley, California • San Diego, California • Vista, California + 11 more

Conditions: Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
Interventions: ERB-041; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 49
States / cities: Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more

Conditions: Lumbar Osteoarthritis, Spondylosis, Lumbar Disc Disease, Spinal Stenosis
Interventions: Ketorolac, Acetaminophen, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 75 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Dulera; Drug
Lead sponsor: Asthma Management Systems; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Depression, Elderly
Interventions: Telepsychology, Face-to-face therapy; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 60 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Diabetes
Interventions: Reciprocal Diabetes Peer Support Program, Nurse Case management, group outpatient counseling visits; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
Interventions: Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib, Venetoclax, Bortezomib, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Methotrexate, Thioguanine; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 4
States / cities: San Diego, California • Charlotte, North Carolina • Tulsa, Oklahoma + 1 more

Conditions: Metabolic Syndrome
Interventions: Indomethacin, Placebo, MRI; Drug · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions: Etelcalcetide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • Louisville, Kentucky • Kansas City, Missouri

Conditions: Diabetes, Gastroparesis With Diabetes Mellitus
Interventions: PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle; Drug · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sleep Apnea, Obesity
Interventions: Positive Airway Pressure During Sleep (ResMed S9 Elite), Usual Care; Device · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anorexia Nervosa
Interventions: Physiologic Estrogen/progesterone, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aging
Interventions: Western Diet, Non-Western Diet; Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 18 Years to 79 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Cognitive Dysfunction, Cognitive Impairment, Cognitive Decline, Cognitive Change
Interventions: CAMCI, MoCA, Clinical Adjudication; Device · Diagnostic Test
Lead sponsor: Psychology Software Tools, Inc.; Industry
Eligibility: 60 Years to 95 Years
Enrollment: 773 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Indianapolis, Indiana • Sharpsburg, Pennsylvania • Houston, Texas + 1 more

Conditions: Sepsis, Hyperglycemia, Critical Illness
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 5 Years to 19 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Delirium, Sleep Hygiene
Interventions: MMSH (Multi-Modal Sleep Hygiene) Bundle; Other
Lead sponsor: Farhaan S. Vahidy; Other
Eligibility: 70 Years and older
Enrollment: 10,890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Baytown, Texas • Houston, Texas • Sugarland, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 1 Year to 35 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Santa Barbara, California • Tallahassee, Florida • Iowa City, Iowa + 4 more

Conditions: Anxiety Sensitivity
Interventions: Aerobic Exercise; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus, RSV, Rhinovirus
Interventions: Aptitude Medical Systems Respiratory Panel Test; Diagnostic Test
Lead sponsor: Aptitude Medical Systems; Industry
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Trussville, Alabama

Search by objective public record fields.

Pyloric Sphincter Pressure and Geometry Assessment Using EndoFlip

Sound Levels in the Pediatric Cardiac Critical Care Unit and Their Correlation With Sedation Administration, Delirium Scores and Patient Heart Rate

Genetic Factors in Age-Related Macular Degeneration

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women

Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes

Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence

Telepsychology-Service Delivery for Depressed Elderly Veterans

Improving Insulin Therapy With Enhanced Care Management

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis

The Effects of Treating Obese and Lean Patients With Sleep Apnea

Effects of Anorexia Nervosa on Bone Mass in Adolescents

Age-associated Arterial Dysfunction, Western Diet, and Aerobic Exercise: Role of the Gut Microbiome

CAMCI: Advancing the Use of Computerized Screening in Healthcare

Gluconeogenesis Rates and Its Precursors in Pediatric Sepsis

Modifying the Inpatient Environment to Reduce Delirium in Older Adults

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

Anxiety, Mood, and Health Behaviors in Young Adults

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings